Search

Your search keyword '"Tonini G."' showing total 2,341 results

Search Constraints

Start Over You searched for: Author "Tonini G." Remove constraint Author: "Tonini G."
2,341 results on '"Tonini G."'

Search Results

2. S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models

3. Short-Term Benefits of Smoking Cessation Improve Respiratory Function and Metabolism in Smokers

4. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

8. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

10. Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain

12. A Staphylococcus aureus Coinfection on a COVID-19 Pneumonia in a Breast Cancer Patient

13. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

15. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

16. Cascade of two-dimensional Fulde-Ferrell-Larkin-Ovchinnikov phases with anisotropy

18. Bone metastases in biliary cancers: A multicenter retrospective survey

19. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

20. Two tricritical lines from a Ginzburg-Landau expansion: application to the LOFF phase

21. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.

25. 108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)

26. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

28. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial

29. Study of tin and gold halos in the medieval wall painting depicting Saints Luke the Evangelist and Gregory the Great in Palermo’s San Francesco d’Assisi church

30. The 3D modelling of musive surfaces for a monitoring protocol

33. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

34. Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study

36. LBA22 Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study

37. 422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018)

38. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial

39. LBA51 Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial

41. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

42. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

43. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients

44. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

45. Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia

46. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

47. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

48. Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study (Archives of Dermatological Research, (2022), 314, 6, (593-603), 10.1007/s00403-021-02243-w)

49. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

50. Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies

Catalog

Books, media, physical & digital resources